Radiopharm Theranostics (ASX:RAD)

Radiopharm Theranostics ‘Extends Runway’ to Key Milestones with AU$70M Investments: Report

Description

The AU$7.5 million strategic investment from Lanthues Holdings signals a strong endorsement of Radiopharm Theranostics’ (ASX:RAD) technology, extending the company's runway to key milestones, according to a new report from Diamond Equity Research.


The anticipated acceleration in growth from the capital infusion and asset development synergy underscores the strategic significance of this partnership.

“This collaboration is pivotal, as Lantheus's expertise and established market presence in key regions, such as the US, Canada and Europe, significantly enhance the strategic value of their investment in Radiopharm,” the report said.

Under the agreement Lantheus will make an initial strategic equity investment of AU$7.5 million. Lantheus has an option to invest an additional AU$7.5 million within the next six months under the same terms. In addition, will transfer two early preclinical assets to Lantheus for AU$3 million. These assets include a TROP2 targeting nanobody and a LRRC15 targeting mAb.

“The anticipated acceleration in growth from the capital infusion and asset development synergy further underscores the strategic significance of this partnership.”

Highlights of the report:

    • Strategic investment by and asset transfer agreement with Lantheus Holdings mark a significant enhancement in Radiopharm's growth strategy and capital strength
    • Radiopharm has secured firm commitments from institutional and sophisticated investors for a significant capital increase through another placement totaling A$62.5 million.
    • Radiopharm Theranostics is positioned in the growing radiopharmaceutical market, which is projected to reach $9.67 billion by 2026. The company's diversified portfolio targets various cancers, including prostate, breast, renal cell carcinoma, and lung cancer.

    For the full analyst report, click here.

    This content is intended only for persons who reside or access the website in jurisdictions with securities and other applicable laws which permit the distribution and consumption of this content and whose local law recognizes the scope and effect of this Disclaimer, its limitation of liability, and the legal effect of its exclusive jurisdiction and governing law provisions [link to Governing Law section of the Disclaimer page].

    Any investment information contained on this website, including third party research reports, are provided strictly for informational purposes, are general in nature and not tailored for the specific needs of any person, and are not a solicitation or recommendation to purchase or sell a security or intended to provide investment advice. Readers are cautioned to seek the advice of a registered investment advisor regarding the appropriateness of investing in any securities or investment strategies mentioned on this website.

    RAD:AU
    Radiopharm Theranostics

    Radiopharm Theranostics Investor Kit

    • Corporate info
    • Insights
    • Growth strategies
    • Upcoming projects

    GET YOUR FREE INVESTOR KIT

    The Conversation (0)
    Strategic Co-Development Partnership with Lantheus for Aus

    Strategic Co-Development Partnership with Lantheus for Aus

    Radiopharm Theranostics (RAD:AU) has announced Strategic Co-Development Partnership with Lantheus for Aus

    Download the PDF here.

    RAD 202 receives approval to start Phase 1 therapeutic trial

    RAD 202 receives approval to start Phase 1 therapeutic trial

    Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

    Download the PDF here.

    Completion of preclinical data package for RAD 402

    Completion of preclinical data package for RAD 402

    Radiopharm Theranostics (RAD:AU) has announced Completion of preclinical data package for RAD 402

    Download the PDF here.

    Biotech therapy capsule containing DNA strand surrounded by cells.

    Top 4 Canadian Biotech Stocks (Updated January 2025)

    Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare. In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies.

    According to Grandview Research, the global biotech market is expected to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

    Here, the Investing News Network profiles the five best-performing Canadian biotech stocks based on their year-on-year gains.

    Data on Canadian biotech stocks was collected on January 14, 2024, using TradingView's stock screener. Only companies with market capitalizations of over C$50 million at that time were considered. Companies on the TSX, TSXV and CSE were considered, but no TSXV-listed stocks made the list this time. Read on to learn what's been driving these biotech firms.

    Keep reading...Show less
    Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

    Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

    Spoken Nutrition™ is a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification, making Spoken products eligible for use by athletes in several major-league and minor-league organizations, as well as the NCAA. With purchase orders secured from many professional sports teams, including multiple MLB teams for use during Spring Training leading into the 2025 regular baseball season, the launch of Spoken Nutrition™ cements Cizzle Brands Corporation as a global leader in sports nutrition.

    News Provided by Business Wire via QuoteMedia

    Keep reading...Show less
    Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

    Cizzle Brands Launching Spoken Nutrition as its Latest Performance-Driven Brand for Athletes

    Spoken Nutrition™ is a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification, making Spoken products eligible for use by athletes in several major-league and minor-league organizations, as well as the NCAA. With purchase orders secured from many professional sports teams, including multiple MLB teams for use during Spring Training leading into the 2025 regular baseball season, the launch of Spoken Nutrition™ cements Cizzle Brands Corporation as a global leader in sports nutrition.

    News Provided by Business Wire via QuoteMedia

    Keep reading...Show less
    CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

    CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

    With the debut of CWENCH Hydration™ in its first major Canadian grocer, Cizzle Brands anticipates that it will be able to further penetrate the mainstream consumer market alongside the specialty athletic and fitness-related markets. Starting this month, CWENCH Hydration™ mix packets will be offered in the pharmacy section of 47 Metro supermarkets across the province of Ontario.

    News Provided by Business Wire via QuoteMedia

    Keep reading...Show less
    CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

    CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

    With the debut of CWENCH Hydration™ in its first major Canadian grocer, Cizzle Brands anticipates that it will be able to further penetrate the mainstream consumer market alongside the specialty athletic and fitness-related markets. Starting this month, CWENCH Hydration™ mix packets will be offered in the pharmacy section of 47 Metro supermarkets across the province of Ontario.

    News Provided by Business Wire via QuoteMedia

    Keep reading...Show less
    Radiopharm Theranostics

    Radiopharm Theranostics Investor Kit

    • Corporate info
    • Insights
    • Growth strategies
    • Upcoming projects

    GET YOUR FREE INVESTOR KIT

    Latest Press Releases

    Related News

    ×